Artificial-Intelligence-Assisted Discovery of Genetic Factors for Precision Medicine of Antiplatelet Therapy in Diabetic Peripheral Artery Disease

• Published in: Biomedicines Vol. 10; no. 1; p. 116
• Main Authors: Yeh, Chi-Hsiao, Chou, Yi-Ju, Tsai, Tsung-Hsien, Hsu, Paul Wei-Che, Li, Chun-Hsien, Chan, Yun-Hsuan, Tsai, Shih-Feng, Ng, Soh-Ching, Chou, Kuei-Mei, Lin, Yu-Ching, Juan, Yu-Hsiang, Fu, Tieh-Cheng, Lai, Chi-Chun, Sytwu, Huey-Kang, Tsai, Ting-Fen
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 06.01.2022; MDPI
• Subjects: Acute coronary syndromes; Amputation; Artificial intelligence; Aspirin; Blood platelets; Cardiovascular disease; Cardiovascular diseases; Clopidogrel; CYP2C19; Diabetes; Diabetes mellitus; diabetic peripheral artery disease; Endocytosis; Enzymes; Genetic factors; Genome-wide association studies; Genomes; Heart attacks; Ischemia; Patients; Precision medicine; Protein turnover; Single-nucleotide polymorphism; Therapeutic targets; ticagrelor; Vascular diseases; Vein & artery diseases; United States > US; Taiwan; clopidogrel; ticagrelor; CYP2C19; single nucleotide polymorphism; artificial intelligence; diabetic peripheral artery disease
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines10010116

An increased risk of cardiovascular events was identified in patients with peripheral artery disease (PAD). Clopidogrel is one of the most widely used antiplatelet medications. However, there are heterogeneous outcomes when clopidogrel is used to prevent cardiovascular events in PAD patients. Here, we use an artificial intelligence (AI)-assisted methodology to identify genetic factors potentially involved in the clopidogrel-resistant mechanism, which is currently unclear. Several discoveries can be pinpointed. Firstly, a high proportion (>50%) of clopidogrel resistance was found among diabetic PAD patients in Taiwan. Interestingly, our result suggests that platelet function test-guided antiplatelet therapy appears to reduce the post-interventional occurrence of major adverse cerebrovascular and cardiac events in diabetic PAD patients. Secondly, AI-assisted genome-wide association study of a single-nucleotide polymorphism (SNP) database identified a SNP signature composed of 20 SNPs, which are mapped into 9 protein-coding genes (SLC37A2, IQSEC1, WASHC3, PSD3, BTBD7, GLIS3, PRDM11, LRBA1, and CNR1). Finally, analysis of the protein connectivity map revealed that LRBA, GLIS3, BTBD7, IQSEC1, and PSD3 appear to form a protein interaction network. Intriguingly, the genetic factors seem to pinpoint a pathway related to endocytosis and recycling of P2Y12 receptor, which is the drug target of clopidogrel. Our findings reveal that a combination of AI-assisted discovery of SNP signatures and clinical parameters has the potential to develop an ethnic-specific precision medicine for antiplatelet therapy in diabetic PAD patients.